Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2013; 19(46): 8687-8695
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8687
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8687
Figure 1 Computed tomography and 68Ga-DOTATOC-PET-Computed tomography images before and during treatment with somatostatin analogue (sandostatin LAR 30 mg/mo).
Pathologic uptake in the gastric and hepatic lesion (A + B) adjacent lymphadenopathy and liver lesion (C + D), disappeared on follow up imaging (E - H).
- Citation: Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: A real threat or just a myth? World J Gastroenterol 2013; 19(46): 8687-8695
- URL: https://www.wjgnet.com/1007-9327/full/v19/i46/8687.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i46.8687